奥赛康(002755) - 2019 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2019 was CNY 1,113,535,599.62, representing a 13.96% increase compared to CNY 977,087,320.30 in the same period last year[7]. - Net profit attributable to shareholders for Q1 2019 was CNY 188,023,269.18, up 17.93% from CNY 159,438,500.27 in the previous year[7]. - Basic and diluted earnings per share for Q1 2019 were both CNY 0.20, a decrease of 4.76% from CNY 0.21 in the previous year[7]. - Total operating revenue for the current period reached ¥1,113,535,599.62, an increase of 13.9% compared to ¥977,087,320.30 in the previous period[44]. - Net profit for the current period was ¥187,667,348.88, representing a 17.9% increase from ¥159,200,125.57 in the previous period[46]. - Operating profit increased to ¥212,489,202.56, compared to ¥188,180,653.07 in the last period, reflecting a growth of 12.8%[46]. - The company reported a total comprehensive income of ¥185,858,570.74, compared to ¥158,628,207.52 in the previous period, indicating a growth of 17.1%[48]. - The total profit for the current period was ¥221,822,510.32, up from ¥189,042,707.74 in the previous period, marking an increase of 17.3%[46]. Cash Flow - The net cash flow from operating activities decreased significantly by 78.02%, amounting to CNY 37,811,213.57 compared to CNY 172,004,533.77 in the same period last year[7]. - Cash inflow from operating activities totaled 1,236,329,186.71 RMB, down from 1,340,176,148.85 RMB in the previous period, representing a decrease of approximately 7.8%[58]. - Cash outflow from investment activities was 419,884,238.54 RMB, compared to 1,134,908,736.06 RMB in the previous period, indicating a decrease of approximately 63.0%[60]. - Cash flow from financing activities was negative, with a net cash flow of -169,218.75 RMB, indicating a decrease in financing activities compared to the previous period[60]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,093,706,956.76, reflecting a 4.58% increase from CNY 2,958,254,506.16 at the end of the previous year[7]. - The total liabilities of Beijing Ausun Pharmaceutical Co., Ltd. amounted to CNY 1,060,211,999.13, a decrease of 5.1% from CNY 1,117,268,276.05 in the previous period[34]. - The total current liabilities decreased to CNY 984,101,415.66, down from CNY 1,040,937,817.00, showing a reduction of 5.4%[34]. - The total non-current liabilities remained relatively stable at CNY 76,110,583.47 compared to CNY 76,330,459.05[34]. - The total equity attributable to the parent company increased to CNY 2,031,108,730.99, up by 10.5% from CNY 1,838,218,276.89[36]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 19,953[11]. - The company's retained earnings rose to CNY 897,186,202.82, an increase of 27.7% from CNY 702,512,776.86[36]. Government Subsidies and Other Income - The company received government subsidies amounting to CNY 10,361,273.62 during the reporting period[7]. - Other income surged by 1,005.57% to ¥9,969,662.78 mainly from increased government subsidies[18]. - The company reported non-operating income and expenses totaling CNY 9,164,041.79 after tax impacts[7]. Accounting Policies and Adjustments - The company adopted new financial instrument standards effective January 1, 2019, which includes changes in the classification and measurement of financial assets[72]. - The new accounting policy emphasizes the expected loss model for financial asset impairment, enhancing the timeliness of loss provisions[75]. - The company has not restated the 2018 financial indicators due to the new accounting policy changes[76].